Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

被引：4

作者：

Song, Yuqin ^{[1
]}

Wu, Shang-Ju ^{[2
]}

Shen, Zhixiang ^{[3
]}

Zhao, Donglu ^{[4
]}

Chan, Thomas Sau Yan ^{[5
]}

Huang, Huiqiang ^{[6
]}

Qiu, Lugui ^{[7
]}

Li, Jianyong ^{[8
]}

Tan, Tran-der ^{[9
]}

Zhu, Jun ^{[1
]}

Song, Yongping ^{[10
]}

Huang, Wei-Han ^{[11
]}

Zhao, Weili ^{[3
]}

Liu, Herman Sung Yu ^{[12
]}

Xu, Wei ^{[8
]}

Chen, Naizhi ^{[13
]}

Ma, Jun ^{[4
]}

Chang, Cheng-Shyong ^{[14
,15
]}

Tse, Eric Wai Choi ^{[16
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China

[2] Natl Taiwan Univ Hosp, Dept Internal Med, Hematol Div, Taipei, Taiwan

[3] Shanghai Jiao Tong Univ, Affiliated Ruijin Hosp, Shanghai, Peoples R China

[4] Harbin Hematol & Oncol Inst, Harbin 150007, Heilongjiang, Peoples R China

[5] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[6] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[7] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[8] Jiangsu Prov Peoples Hosp, Nanjing, Jiangsu, Peoples R China

[9] Koo Fdn, Sun Yat Sen Canc Ctr, Dept Hematol & Med Oncol, Taipei, Taiwan

[10] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China

[11] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Clin Pathol, Hualien, Taiwan

[12] Premier Med Ctr, Hong Kong, Peoples R China

[13] Macau Soc Hematol & Oncol, Macau, Peoples R China

[14] Chang Bing Show Chwan Mem Hosp, Dept Internal Med, Div Hematol Oncol, Lukang, Taiwan

[15] Cent Taiwan Univ Sci & Technol, Dept Healthcare Adm, Taichung, Taiwan

[16] Univ Hong Kong, Sch Clin Med, Dept Med, Hong Kong, Peoples R China

来源：

EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期

关键词：

BTK inhibitors; China; Consensus; Non-Hodgkin lymphoma; Targeted therapy; CHRONIC LYMPHOCYTIC-LEUKEMIA; NERVOUS-SYSTEM LYMPHOMA; MARGINAL ZONE LYMPHOMA; TERM-FOLLOW-UP; WALDENSTROM MACROGLOBULINEMIA; PHASE-II; SINGLE-ARM; ACALABRUTINIB MONOTHERAPY; IBRUTINIB MONOTHERAPY; ATRIAL-FIBRILLATION;

D O I：

10.1186/s40164-023-00448-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies. Considering the unmet need of evidence on BTK inhibitors in all clinical settings and to standardize the use of BTK inhibitors available in mainland China, Taiwan, Hong Kong, and Macau regions, this consensus has been formulated for the treatment of various B-cell malignancies based on the clinical practice and available evidences on the use of BTK inhibitors. The recommendations of this consensus will provide guidance to physicians and clinical researchers on the effective treatment of B-cell malignancies with BTK inhibitors.

引用

页数：26

共 179 条

[1]

accessdata.fda, 2017, CALQUENCE (acalabrutinib) capsules, for oral use

[2] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[3] Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 [J].

Al-Hamadani, Mohammed ;

Habermann, Thomas M. ;

Cerhan, James R. ;

Macon, William R. ;

Maurer, Matthew J. ;

Go, Ronald S. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (09) :790-795

[4] Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region [J].

Alshemmari, Salem H. ;

Siddiqui, Mustaqeem A. ;

Pandita, Ramesh ;

Osman, Hani Y. ;

Cherif, Honar ;

O'Brien, Susan ;

Marashi, Mahmoud ;

Al Farsi, Khalil .

ACTA HAEMATOLOGICA, 2023, :260-279

[5] BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies [J].

Alu, Aqu ;

Lei, Hong ;

Han, Xuejiao ;

Wei, Yuquan ;

Wei, Xiawei .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

[6] Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial [J].

An, Gang ;

Zhou, Daobin ;

Zhao, Weili ;

Zhou, Keshu ;

Li, Jianyong ;

Zhou, Jianfeng ;

Xie, Liping ;

Jin, Jie ;

Zhong, Liye ;

Yan, Lingzhi ;

Guo, Haiyi ;

Du, Chenmu ;

Huang, Jane ;

Novotny, William ;

Zhong, Jinhua ;

Qiu, Lugui .

BLOOD, 2020, 136

[7]

[Anonymous], 2019, package insert

[8]

[Anonymous], LOXO LILLY PRESENTS

[9]

[Anonymous], Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment ofcentralnervous systemlymphoma: a retrospective study, DOI [10.1007/s10637-022-01219-5, DOI 10.1007/S10637-022-01219-5]

[10]

[Anonymous], Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

← 1 2 3 4 5 6 7 8 9 10 →